WR Berkley
WRB
69.73
+0.08
+0.11%
WR Berkley
US · WRB
#785 by market cap
Listed 1970
69.73
+0.08
+0.11%
Live - 5344 symbols - heartbeat 23s ago
· 2026-10-07 20:02
After-hours
69.73
0.00%
- Market cap
- 25.89B
- P/E (TTM)i
- 14.35
- P/Bi
- 2.63
- EPSi
- 4.45
- Div yieldi
- 0.53%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on WRB?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 10 analysts
Hold
Avg price target
72.60 +4.1%
Price target rangecurrent 69.73
Low62.00
Avg72.60
High83.00
Buy 20%
Hold 40%
Sell 40%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-15 | Mizuho Securities | -- | HOLD | 72.00 |
| 2026-07-27 | UBS | -- | HOLD | 77.00 |
| 2026-07-22 | Morgan Stanley | -- | HOLD | 75.00 |
| 2026-07-21 | Wells Fargo | -- | SELL | 68.00 |
| 2026-07-21 | Mizuho Securities | -- | HOLD | 74.00 |
| 2026-07-21 | Truist Financial | -- | BUY | 83.00 |
| 2026-07-20 | Cantor Fitzgerald | -- | HOLD | 74.00 |
| 2026-07-20 | BofA Securities | -- | SELL | 69.00 |
| 2026-07-20 | Morgan Stanley | -- | HOLD | 75.00 |
| 2026-07-20 | Goldman Sachs | -- | BUY | 78.00 |
| 2026-07-20 | Barclays | -- | SELL | 62.00 |
| 2026-07-16 | BofA Securities | -- | SELL | 68.00 |
| 2026-07-15 | BofA Securities | -- | HOLD | -- |
| 2026-07-10 | Evercore | -- | SELL | 68.00 |
| 2026-07-09 | Cantor Fitzgerald | -- | HOLD | 74.00 |
| 2026-07-09 | Mizuho Securities | -- | HOLD | 72.00 |
| 2026-07-07 | Barclays | -- | SELL | 62.00 |
| 2026-07-06 | Morgan Stanley | -- | HOLD | 75.00 |
| 2026-06-12 | Barclays | -- | SELL | 62.00 |
| 2026-06-08 | Wells Fargo | -- | SELL | 58.00 |
| 2026-06-08 | Goldman Sachs | -- | BUY | 73.00 |
| 2026-04-27 | Argus Research | -- | HOLD | -- |
| 2026-04-27 | UBS | -- | HOLD | 68.00 |
| 2026-04-23 | Mizuho Securities | -- | HOLD | 68.00 |
| 2026-04-23 | BMO Capital | -- | HOLD | 68.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Sell
Analyst consensus
Hold
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
2 3
■ Upgrades■ Downgrades
- 2 upgrades vs 3 downgrades among tracked analyst rating changes.
- Most recent: BofA Securities moved from Hold to Sell on 2026-07-16.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-07-16 | BofA Securities | HOLD → SELL | 68.00 |
| 2026-06-08 | Goldman Sachs | HOLD → BUY | 73.00 |
| 2026-04-23 | BMO Capital | SELL → HOLD | 68.00 |
| 2026-04-09 | Cantor Fitzgerald | BUY → HOLD | 71.00 |
| 2025-11-07 | UBS | BUY → HOLD | 78.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-20 | After close | ±5.49% | -0.78% (in line) |
| 2026/Q1 | 2026-04-21 | After close | ±6.34% | +3.21% (in line) |
| 2025/Q4 | 2026-01-26 | After close | ±4.66% | +0.52% (in line) |
| 2025/Q3 | 2025-10-20 | After close | ±5.60% | +2.07% (in line) |
| 2025/Q2 | 2025-07-21 | After close | ±5.69% | +1.09% (in line) |
| 2025/Q1 | 2025-04-21 | After close | ±7.40% | +5.23% (in line) |
| 2024/Q4 | 2025-01-27 | After close | ±6.10% | +0.24% (in line) |
| 2024/Q3 | 2024-10-21 | After close | ±6.71% | -4.10% (in line) |
| 2024/Q2 | 2024-07-22 | After close | ±5.77% | +0.75% (in line) |
| 2024/Q1 | 2024-04-23 | -- | ±6.24% | -5.21% (in line) |
| 2023/Q4 | 2024-01-24 | After close | ±5.14% | +7.18% (beat) |
| 2023/Q3 | 2023-10-23 | After close | ±5.66% | +6.15% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-07 20:02:29 · For reference only, not investment advice and not tailored to your situation.